2-amino-9-[(2R,3R,5S)-3-fluoro-5-(hydroxymethyl)-3-methyloxolan-2-yl]-1H-purin-6-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-amino-9-[(2R,3R,5S)-3-fluoro-5-(hydroxymethyl)-3-methyloxolan-2-yl]-1H-purin-6-one
• 化学式: C₁₁H₁₄FN₅O₃
• 分子量: 283.26
• InChiKey: LPYLSVDILUUXGP-CRWVSBFASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  115
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• 4'-FLUORO-NUCLEOSIDES, 4'-FLUORO-NUCLEOTIDES AND ANALOGS THEREOF FOR THE TREATMENT OF HCV
  申请人：Janssen BioPharma, Inc.

  公开号：EP2935303B1

  公开（公告）日：2021-02-17
• 3'-DEOXY NUCLEOSIDES FOR THE TREATMENT OF HCV
  申请人：Idenix Pharmaceuticals, Inc.

  公开号：US20140248241A1

  公开（公告）日：2014-09-04

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3′-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base 1 and Base 2 are as provided herein.
• US9309275B2
  申请人：——

  公开号：US9309275B2

  公开（公告）日：2016-04-12
• [EN] 3'-DEOXY NUCLEOSIDES FOR THE TREATMENT OF HCV<br/>[FR] 3'-DÉSOXYNUCLÉOSIDES UTILISABLES EN VUE DU TRAITEMENT D'UNE INFECTION PAR LE VHC
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2014137926A1

  公开（公告）日：2014-09-12

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3'- deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base1 and Base2 are as provided herein.